- Home
- IDAI vs TCBP Comparison
IDAI vs TCBP Comparison
Compare IDAI & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- TCBP
- Stock Information
- Founded
- IDAI 2016
- TCBP 2013
- Country
- IDAI United States
- TCBP United Kingdom
- Employees
- IDAI N/A
- TCBP N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IDAI Technology
- TCBP Health Care
- Exchange
- IDAI Nasdaq
- TCBP Nasdaq
- Market Cap
- IDAI 4.0M
- TCBP 3.0M
- IPO Year
- IDAI N/A
- TCBP 2022
- Fundamental
- Price
- IDAI $0.24
- TCBP $6.93
- Analyst Decision
- IDAI
- TCBP
- Analyst Count
- IDAI 0
- TCBP 0
- Target Price
- IDAI N/A
- TCBP N/A
- AVG Volume (30 Days)
- IDAI 305.4K
- TCBP 529.9K
- Earning Date
- IDAI 11-05-2024
- TCBP 11-09-2024
- Dividend Yield
- IDAI N/A
- TCBP N/A
- EPS Growth
- IDAI N/A
- TCBP N/A
- EPS
- IDAI N/A
- TCBP N/A
- Revenue
- IDAI $4,714,908.00
- TCBP N/A
- Revenue This Year
- IDAI N/A
- TCBP N/A
- Revenue Next Year
- IDAI $215.04
- TCBP N/A
- P/E Ratio
- IDAI N/A
- TCBP N/A
- Revenue Growth
- IDAI 69.90
- TCBP N/A
- 52 Week Low
- IDAI $0.21
- TCBP $2.11
- 52 Week High
- IDAI $2.50
- TCBP $1,140.00
- Technical
- Relative Strength Index (RSI)
- IDAI 30.30
- TCBP 56.83
- Support Level
- IDAI $0.23
- TCBP $4.32
- Resistance Level
- IDAI $0.26
- TCBP $8.15
- Average True Range (ATR)
- IDAI 0.03
- TCBP 1.57
- MACD
- IDAI -0.00
- TCBP 0.20
- Stochastic Oscillator
- IDAI 11.90
- TCBP 59.60
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.